Aurora Cannabis reported a 17% increase in international medical cannabis revenue to C$43.3 million in its fiscal first quarter ended June 30, 2026, even as total net revenue fell 9% to C$67.6 million due to a Canadian reimbursement cut and the wind-down of its consumer business. Adjusted gross margin reached 58%, the high end of the company's full-year guidance, while adjusted EBITDA declined to C$3.4 million from C$10.8 million a year earlier. The company's newly acquired Safari facility contributed positively to adjusted EBITDA in its first quarter and received a three-year EU-GMP certification, expanding internal supply for high-margin international markets. Management expects higher second-quarter revenue and adjusted EBITDA, and Street estimates point to a return to growth and positive free cash flow in fiscal 2028. Aurora ended the quarter with C$149.1 million in cash, restricted cash, and short-term investments and no debt.
Aurora Cannabis IncInternational medical revenue rose 17% to C$43.3M, and the Safari facility received EU-GMP certification, expanding high-margin supply.
Canopy Growth Corp
Cronos Group Inc
SNDL Inc.
Tilray Inc